Newsdeck

Newsdeck

Chinese drugmakers agree to supply more than half a billion vaccines to COVAX

epa09038185 Workers unload boxes with the Oxford/AstraZeneca vaccine as the country receives its first batch of COVID-19 vaccines under the COVAX scheme, in Abidjan, Ivory Coast, 26 February 2021. Some 500,000 doses of the Oxford/Astrazeneca vaccine were received in Abidjan before the vaccination plan COVID-19 begins on 01 March. (Photo: EPA-EFE/LEGNAN KOULA)
By Reuters
12 Jul 2021 0

GENEVA, July 12 (Reuters) - The Global Alliance for Vaccines and Immunization (GAVI) said on Monday it had signed two advance purchase agreements with Chinese drugmakers Sinopharm and Sinovac to provide up to 550 million COVID-19 vaccines to the COVAX programme.

By Emma Farge

The new deals include up to 170 million doses of the Sinopharm shot and up to 380 million shots of the Sinovac vaccine, through to the middle of 2022, the statement said. Sinovac confirmed the agreement in a statement.

“The agreements, which come at a time when the Delta variant is posing a rising risk to health systems, will begin to make 110 million doses immediately available to participants of the COVAX Facility, with options for additional doses,” GAVI said.

GAVI, which runs the global vaccine sharing scheme COVAX with the World Health Organization (WHO) did not immediately provide details of which countries would receive the doses.

Deliveries can start quickly because both vaccines have already been granted emergency use listing by the WHO, GAVI Chief Executive Officer Seth Berkley said.

“This is yet another example of Gavi’s active portfolio management strategy, ensuring the Facility has options in the face of constraints such as supply delays,” he added.

COVAX, which distributes vaccines to poorer countries, has struggled to meet its early commitments amid Indian export disruptions, forcing many countries to freeze their inoculation programmes in their early phases.

However, its latest supply forecast shows that the programme is on track to deliver more than 2 billion doses by early 2022. Sinovac and Sinopharm join nine other vaccines and vaccine candidates already in the programme including those by AstraZeneca and Moderna.

Some countries including Thailand and Indonesia which used Sinovac as a first dose are switching to other shots for the second dose to increase protection against COVID-19.

GAVI did not immediately respond to a request for comment about whether it had concerns about the vaccine’s efficacy. (Reporting by Emma Farge; Editing by Edmund Blair and Emelia Sithole-Matarise)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery